NICE recommends wider use of Biogen MS drug via NHS
NICE has backed NHS use of natalizumab, a key treatment option that is safe for use in pregnancy, for more patients with multiple sclerosis.
China delivers a win for Novo Nordisk on semaglutide IP
Novo Nordisk has been handed a crucial legal win by China's Supreme Court, which backed the validity of its patent on GLP-1 agonist semaglutide.
FDA declines to approve Corcept's rare disorder drug
As the celebrations for the end of 2025 gathered pace, the FDA delivered a year-end blow to Corcept by turning down its new Cushing's drug.
Genmab ends lung cancer drug development
Genmab has decided to stop development of a drug for cancer, acasunlimab for non-small cell lung cancer, following a review of its pipeline.
Vanda ends 40-year hiatus for new motion sickness drugs
The FDA has delivered some end-of-year cheer to Vanda Pharma after approving Nereus, its drug for the prevention of motion sickness.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
5th mRNA-Based Therapeutics Summit Europe
The Summit is the leading European industry-focused forum dedicated to accelerating the development of messenger RNA (mRNA) medicines
VuuAI and Amiculum partner to transform content engagement i...
Amiculum, a global health communications agency, has entered into an exciting strategic collaboration with VuuAI, a GenAI-driven content production automation plat
10th Tumor Models Summit San Francisco
Join the West Coast's premier pharma and biotech gathering, the 10th Tumor Models Summit San Francisco, where innovation meets opportunity
The PM Society Careers Event – 18th February 2026
Join us for our popular event to see how your skills and interests could add value to this vital and constantly evolving industry.
Frontiers Health Turns 10
Celebrating a Decade of Innovation and Collaboration in Berlin, November 11–12, 2025 Berlin / November 7th, 2025 | Marking its 10th anniversary,